“Inheritance, innovation and development” is the key word of the traditional Chinese medicine industry, and since 2019, corresponding guidelines have been issued at the national level and in many provinces. It is not difficult to find that accelerating the modernization and industrialization of traditional Chinese medicine is the due meaning of the high-quality development of traditional Chinese medicine.
In recent years, China’s traditional Chinese medicine industry has developed rapidly, and the scale of the industry has been rising, but there are also multiple challenges, and problems such as the fragmentation of the traditional Chinese medicine industry chain, the fault between clinical and scientific research, and the disconnect between research and application still exist. On the other hand, there are also many obstacles in the “journey” of modern Chinese medicine to the sea.
The strong chain of traditional Chinese medicine industry cannot be separated from the investment of modern science and technology.
At the Third TCM High-quality Development Conference held in April 2024, Zhang Boli, academician of the Chinese Academy of Engineering, pointed out that the integration of traditional Chinese medicine and modern science and technology has opened up a path of inheritance, innovation and development, formed a significant disciplinary advantage, led the development of the health industry, and produced significant social and economic benefits.
Reflected in the data, according to statistics, in 2022, China’s traditional Chinese medicine market size of nearly 450 billion yuan, 2023 growth to more than 480 billion yuan, this year is expected to exceed 500 billion yuan. However, there are still multiple challenges in the high-quality development of the Chinese medicine industry, the first of which is the fragmentation of the Chinese medicine industry chain and the failure to form effective industrial synergy.
“The development of every industry should be the common development of the whole industrial chain, the chain strong industry is strong, and the chain weak industry is weak.” The traditional Chinese medicine industry chain is very long, so it leads to some disjointed phenomenon.”
Geng Fu can say that the traditional Chinese medicine industry chain covers all aspects from the “head of the field” to the “head of the bed”, so it is more difficult to build the whole industry chain.
From the practice of Good Doctor Group, the company emphasizes the construction of the “first workshop” and builds a standardized planting system to lay a good foundation for drug consistency and controllability.
Geng Fu Neng said: “The first production workshop of Chinese medicine is in the soil. Planting is the first link in the traditional Chinese medicine industry chain, and if the raw materials are not good, no matter through GMP (Good manufacturing Practice) or any other method, there is no way to correct it in the production of proprietary medicines.”
Therefore, in the “area”, it is necessary to do a good job of selection and breeding of excellent varieties, “that is, to ensure the authenticity of Chinese medicinal materials”, which is a prerequisite. But the good source is not easy, because Chinese herbal medicine planting involves agriculture, forestry, land and other departments, “for example, land belongs to the management of land resources, mountain herbs and animals belong to forestry management, involving a very wide range of departments, need to work together.”
Medicinal materials out, but also through the processing of traditional Chinese medicine slices, to the production of proprietary Chinese medicine, that is, the scope of the factory. For this link, the state has formulated relevant standards and certification rules, but in Geng Fueng’s view, traditional Chinese medicine production enterprises “can not lie on the achievements of the ancestors to survive”, but should continue to strengthen scientific research investment, so that the production of proprietary Chinese medicine to keep up with the pace of The Times.
“Whether it is Chinese medicine or Western medicine, whether it is effective is the key, after confirming the effectiveness, we also need to study what is working, how it works, and what the process is like.” Geng Fu can say that only by answering these “four questions” can we promote the upgrading of traditional Chinese medicine products. If we want to answer the “four questions”, we cannot do without the investment of modern science and technology.
In 2024, the Good Doctor Group will promote 13 innovative drug projects and 12 generic drug projects. At present, the GD-N1801 project of Good Doctor Group’s class 1 innovative drug has obtained the National CDE (Drug Evaluation Center of the State Drug Administration) drug clinical trial approval notice, and clinical trials are about to start. In addition, the company’s innovative drug products GD-N1702, GD-N1901, etc., have also entered the clinical trial stage.
“The difference and connection between modern Chinese medicine and traditional Chinese medicine is that modern Chinese medicine needs to interpret traditional Chinese medicine.” Geng Funeng cited GD-N1702 as an example, which is an ingredient found in aconite in cooperation with the scientific research team of the West China College of Pharmacy at Sichuan University.
“Aconite is the four beams and eight pillars in traditional Chinese medicine, its effect is to return Yang to save the adverse, replenish the true fire of congenital life gate, return Yang to save the adverse simple understanding is to have a strong heart function.” GD-N1702, which has been discovered, can repair the mitochondria of cardiac muscle cells and can be used to treat chronic heart failure.
Similarly, GD-N1801 is a new component found in the extract of the American cockroach. Geng Funeng introduced that this new ingredient is a polypeptide composed of amino acids, which is more effective than another good doctor’s product Kangfuxin solution in the treatment of chronic wounds, such as diabetic foot ulcers, pressure ulcers and other body surface wounds. “This product has been approved for phase I clinical studies, and if it can successfully enter the market, it will fill many gaps in clinical practice.
Related topics
